Rilotumumab and Erlotinib Hydrochloride in Treating Patients With Recurrent or Progressive Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy

Inclusion Criteria

• Patients with recurrent or progressive advanced stage NSCLC (no small cell lung cancer [SCLC] component) who have been treated with at least one and a maximum of two prior chemotherapy regimens for advanced NSCLC; chemotherapy as part of initial potentially curative therapy (given as part of adjuvant or concomitant chemoradiotherapy) that was completed < 1 year counts as 1 prior regimen; prior erlotinib, other EGFR tyrosine-kinase inhibitors (TKIs) or monoclonal antibodies targeting EGFR are not allowed; NOTE: Chemotherapy as part of initial potentially curative therapy (given as part of adjuvant or concomitant chemoradiotherapy) that was completed one or more years prior to screening for this study does not count as a prior regimen; if the tumor is refractory (progressed) after a prior chemotherapy regimen, then that regimen would count; if a prior chemotherapy regimen has been changed due to other reasons than disease progression (e.g. poor tolerance, allergic reaction), then it would not count as a separate prior regimen; a chemotherapy drug added for “maintenance” following disease stabilization or response to a chemotherapy regimen (in the absence of prior disease progression) does not count as a separate prior regimen; NOTE: Pathology reports documenting the diagnosis of NSCLC are required to be reviewed by the screening physician investigator
• Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (for phase II part only)
• Eastern Cooperative Oncology Group (ECOG) performance status of =< 2; NOTE: For the phase I part of the study, patients with ECOG performance status 2 will be excluded
• Life expectancy of >= 3 months
• Absolute neutrophil count (ANC) >= 1500/mm^3
• Platelets >= 100,000/mm^3
• Hemoglobin >= 9 g/dL
• International normalized ratio (INR) =< 1.5 or
• Prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution
• Total bilirubin within normal institutional limits
• Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 2.5 x upper limit of normal (ULN), except if there is known hepatic metastasis, wherein transaminases may be =< 5 x institutional ULN
• Creatinine clearance 45 ml/min or higher calculated using the Cockcroft-Gault formula
• Patients must have fully recovered from the effects of any prior surgery, chemotherapy or radiation therapy; a minimum time period of 3 weeks should elapse between the completion of radiation therapy for recurrent/metastatic disease and enrollment in the study; a minimum of 4 weeks should elapse between the completion of chemotherapy or any experimental therapy and enrollment in the study; a minimum of 4 weeks should elapse between prior major surgery (such as open biopsy or significant traumatic injury) and enrollment in the study; a minimum of 2 weeks should elapse between prior minor surgical procedures (such as chemotherapy infusion port placement or core visceral organ biopsy) and enrollment in the study
• If patient has history of brain metastases, brain lesions should have been treated with surgery and/or radiation and be stable on repeat imaging and patients should be neurologically stable on a stable or tapering dose of corticosteroids
• No history of prior malignancy, with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer, unless there is a 3-year disease-free interval
• Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 7 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method or abstain from sexual activity during the study and for 3 months after last study drug administration; sexually active males and their female partners must agree to use two methods of accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study
• All patients must have given signed, informed consent prior to registration on study

Exclusion Criteria

• Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required; this is due to the unknown effects of AMG102
• Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
• Patients who have mixed tumors with small-cell elements are ineligible
• Pregnancy or lactation; all females of child-bearing potential must have negative serum or urine pregnancy tests within 7 days prior to starting study treatment
• Prior treatment of NSCLC with EGFR TKIs or monoclonal antibodies targeting EGFR
• A serious active infection (> grade 2) within 7 days of enrollment
• A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment
• Untreated brain metastases
• A major surgical procedure or significant traumatic injury within 28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study; in addition, if a patient has not yet recovered from prior minor surgery (such as central venous access device or fine needle aspiration biopsy)
• Thrombosis or vascular ischemic events within the last twelve months, such as deep venous thrombosis, pulmonary embolism, transient ischemic attack, cerebral infarction, or myocardial infarction
• Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except for the use of low dose coumarin-type anticoagulants or low molecular weight heparin for prophylaxis against central venous catheter thrombosis
• Presence of peripheral edema > Grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 4)